Cam Gallagher - Nov 15, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
President, Director
Signature
By: /s/ Melissa B. Epperly, attorney-in-fact for Cam S. Gallagher
Stock symbol
ZNTL
Transactions as of
Nov 15, 2022
Transactions value $
-$284,683
Form type
4
Date filed
11/15/2022, 06:50 PM
Previous filing
Nov 8, 2022
Next filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Sale -$264K -11.6K -3.02% $22.72 373K Nov 15, 2022 Direct F1, F2
transaction ZNTL Common Stock Sale -$21.1K -900 -0.24% $23.48 372K Nov 15, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.20 to $23.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.21 to $23.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.